31 August 2022>: Clinical Research
Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Patients Receiving 4–6 Cycles of Platinum-Based and Taxane-Based Chemotherapy: A Prospective, Single-Center Study from Kosovo
Blerim Myftiu 12ABCDEFG* , Zylfije Hundozi 12ACDF , Faton Sermaxhaj 3ABD , Afrim Blyta 1ACDF , Nexhmedin Shala 12CD , Fisnik Jashari 12C , Hasime Qorraj Bytyqi 4CDF , Ekrem Hyseni 3BC , Ilir Kurtishi 3BCDOI: 10.12659/MSM.937856
Med Sci Monit 2022; 28:e937856
Table 7 Clinical comparison between platinum-only, taxane-only, and combination groups.
Variable | None | Platinum | Taxane | Combination | Significance |
---|---|---|---|---|---|
Sensory symptoms | 1.50 | 1.95 | 1.47 | 1.73 | p=0.17 |
Motor symptoms | 0.00 | 0.15 | 0.07 | 0.23 | p=0.30 |
Autonomous symptoms | 0.00 | 0.05 | 0.00 | 0.00 | p=0.38 |
Tactile sensitivity | 1.25 | 1.40 | 1.20 | 1.36 | p=0.84 |
Vibration sensitivity | 0.75 | 1.23 | 0.80 | 1.05 | p=0.10 |
Muscle strength | 0.00 | 0.18 | 0.07 | 0.55 | p |
Deep-tendon reflexes | 2.00 | 2.77 | 2.30 | 2.55 | p=0.21 |
Total Neuropathy Score, reduced | 8.5±5.1 (N: 8) | 12.1±5.8 (N: 60) | 9.6±5.5 (N: 30) | 11.6±6.5 (N: 22) | p=0.14 |